Amphastar Pharmaceuticals Inc.

34.28+2.50+7.87%Vol 368.07K1Y Perf 51.91%
Jun 27th, 2022 16:00 DELAYED
BID31.08 ASK38.75
Open32.22 Previous Close31.78
Pre-Market- After-Market34.28
 - -  - -%
Target Price
45.00 
Analyst Rating
Moderate Buy 2.00
Potential %
31.27 
Finscreener Ranking
★★★+     51.67
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★★+     54.01
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★★★     67.94
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
62.16 
Earnings Rating
Sell
Market Cap1.67B 
Earnings Date
8th Aug 2022
Alpha0.01 Standard Deviation0.10
Beta0.65 

Today's Price Range

31.9434.69

52W Range

17.5644.46

5 Year PE Ratio Range

-139.30921.10

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Week
8.45%
1 Month
-11.81%
3 Months
-5.95%
6 Months
50.09%
1 Year
51.91%
3 Years
62.39%
5 Years
93.89%
10 Years
-

TickerPriceChg.Chg.%
AMPH34.282.50007.87
AAPL141.660.00000.00
GOOG2 332.45-38.3100-1.62
MSFT264.89-2.8100-1.05
XOM89.032.13002.45
WFC40.24-0.5200-1.28
JNJ182.12-0.1700-0.09
FB196.640.99000.51
GE66.71-0.2900-0.43
JPM116.38-0.9400-0.80
Earnings HistoryEstimateReportedSurprise %
Q01 20220.330.4742.42
Q04 20210.380.4210.53
Q03 20210.220.46109.09
Q02 20210.210.210.00
Q01 20210.190.2742.11
Q04 20200.140.1614.29
Q03 20200.060.0950.00
Q02 20200.110.1645.45
Earnings Per EndEstimateRevision %Trend
6/2022 QR0.30-11.76Negative
9/2022 QR0.36-14.29Negative
12/2022 FY1.46-8.75Negative
12/2023 FY1.71-13.64Negative
Next Report Date8th Aug 2022
Estimated EPS Next Report0.30
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume368.07K
Shares Outstanding48.83K
Shares Float30.84M
Trades Count9.37K
Dollar Volume12.47M
Avg. Volume669.71K
Avg. Weekly Volume559.88K
Avg. Monthly Volume847.57K
Avg. Quarterly Volume601.67K

Amphastar Pharmaceuticals Inc. (NASDAQ: AMPH) stock closed at 34.28 per share at the end of the most recent trading day (a 7.87% change compared to the prior day closing price) with a volume of 368.07K shares and market capitalization of 1.67B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 2027 people. Amphastar Pharmaceuticals Inc. CEO is Jack Yongfeng Zhang.

The one-year performance of Amphastar Pharmaceuticals Inc. stock is 51.91%, while year-to-date (YTD) performance is 47.19%. AMPH stock has a five-year performance of 93.89%. Its 52-week range is between 17.56 and 44.46, which gives AMPH stock a 52-week price range ratio of 62.16%

Amphastar Pharmaceuticals Inc. currently has a PE ratio of 19.60, a price-to-book (PB) ratio of 3.24, a price-to-sale (PS) ratio of 3.68, a price to cashflow ratio of 12.70, a PEG ratio of 2.32, a ROA of 12.27%, a ROC of 15.49% and a ROE of 18.86%. The company’s profit margin is 18.37%, its EBITDA margin is 29.90%, and its revenue ttm is $455.12 Million , which makes it $9.32 revenue per share.

Of the last four earnings reports from Amphastar Pharmaceuticals Inc., there were 3 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.30 for the next earnings report. Amphastar Pharmaceuticals Inc.’s next earnings report date is 08th Aug 2022.

The consensus rating of Wall Street analysts for Amphastar Pharmaceuticals Inc. is Moderate Buy (2), with a target price of $45, which is +31.27% compared to the current price. The earnings rating for Amphastar Pharmaceuticals Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Amphastar Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Amphastar Pharmaceuticals Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 9.70, ATR14 : 2.05, CCI20 : -46.09, Chaikin Money Flow : -0.07, MACD : -1.14, Money Flow Index : 40.40, ROC : -23.26, RSI : 43.34, STOCH (14,3) : 22.97, STOCH RSI : 0.51, UO : 43.14, Williams %R : -77.03), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Amphastar Pharmaceuticals Inc. in the last 12-months were: Floyd F. Petersen (Option Excercise at a value of $347 179), Floyd F. Petersen (Sold 13 219 shares of value $436 337 ), Howard Lee (Option Excercise at a value of $347 179), Howard Lee (Sold 20 291 shares of value $738 182 ), Jack Yongfeng Zhang (Sold 237 871 shares of value $8 297 123 ), Jacob Liawatidewi (Option Excercise at a value of $545 275), Jacob Liawatidewi (Sold 40 456 shares of value $819 493 ), Michael A. Zasloff (Option Excercise at a value of $347 179), Michael A. Zasloff (Sold 20 291 shares of value $703 569 ), Richard Prins (Option Excercise at a value of $347 179), Richard Prins (Sold 20 291 shares of value $559 314 ), Rong Zhou (Option Excercise at a value of $486 160), Rong Zhou (Sold 61 484 shares of value $1 524 812 ), William J. Peters (Option Excercise at a value of $2 318 597), William J. Peters (Sold 182 836 shares of value $5 178 840 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (50.00 %)
2 (66.67 %)
3 (75.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (50.00 %)
1 (33.33 %)
1 (25.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
2.00
Moderate Buy
1.67
Strong Buy
1.50

Amphastar Pharmaceuticals Inc.

Amphastar Pharmaceuticals Inc is a specialty pharmaceutical company engaged in developing, manufacturing, marketing and selling generic and proprietary injectable and inhalation products. The business activities are operated through two reportable segments namely finished pharmaceutical products and API products. The finished pharmaceutical products segment manufactures, markets and distributes enoxaparin, naloxone, lidocaine, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes RHI API and porcine insulin API. Its products are used in hospitals or urgent care clinical settings. Geographically the business presence of the firm is seen in the United States and France of which the US accounts for the majority of revenue.

CEO: Jack Yongfeng Zhang

Telephone: +1 909 980-9484

Address: 11570 6th Street, Rancho Cucamonga 91730, CA, US

Number of employees: 2 027

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

65%35%

Bearish Bullish

67%33%

Bearish Bullish

60%40%

TipRanks News for AMPH

Thu, 09 Jun 2022 18:05 GMT Amphastar Pharmaceuticals (AMPH) Receives a Hold from Needham

- TipRanks. All rights reserved.

Fri, 08 Apr 2022 14:45 GMT Amphastar Pharmaceuticals (AMPH) Gets a Hold Rating from Needham

- TipRanks. All rights reserved.

News

Stocktwits